Clinical Trial

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

Name: To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT — clinical trial record (NCT07280494)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: S101MRD

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell transplantation

Trial Details

NCT Number	NCT07280494
Lead Sponsor	Peking University People's Hospital
Conditions	CD7+ T-ALL/LBL
Enrollment	18 participants
Start Date	2025-08-18
Primary Completion	2026-08-30 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-12